LARS
Leucine--tRNA ligase, cytoplasmic
Protein Summary
Catalyzes the specific attachment of an amino acid to its cognate tRNA in a two step reaction: the amino acid (AA) is first activated by ATP to form AA-AMP and then transferred to the acceptor end of the tRNA. Exhibits a post-transfer editing activity to hydrolyze mischarged tRNAs. This gene encodes a cytosolic leucine-tRNA synthetase, a member of the class I aminoacyl-tRNA synthetase family. The encoded enzyme catalyzes the ATP-dependent ligation of L-leucine to tRNA(Leu). It is found in the cytoplasm as part of a multisynthetase complex and interacts with the arginine tRNA synthetase through its C-terminal domain. A mutation in this gene was found in affected individuals with infantile liver failure syndrome 1. Alternatively spliced transcript variants of this gene have been observed. [provided by RefSeq, Dec 2015]
- ENST00000274562
- ENSP00000274562
- ENSG00000133706
- ENST00000394434
- ENSP00000377954
- ENST00000510191
- ENSP00000426005
- KIAA1352
- LRS
- LEUS
- LFIS
- ILFS1
- LARS1
- LEURS
- PIG44
- RNTLS
- HSPC192
- hr025Cl
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
disease perturbation | 1 | ||
transcription factor perturbation | 0.98 | ||
protein domain | 0.97 | ||
molecular function | 0.96 | ||
virus perturbation | 0.88 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 486.97 (req: < 5)
Gene RIFs: 24 (req: <= 3)
Antibodies: 98 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 486.97 (req: >= 5)
Gene RIFs: 24 (req: > 3)
Antibodies: 98 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 17
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligands: 13
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0